Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp

[1]  F. Hirsch,et al.  Predicting clinical benefit from EGFR TKIs: Not all EGFR mutations are equal. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Ladanyi,et al.  Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib , 2006, Clinical Cancer Research.

[3]  Patricia L. Harris,et al.  Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Kevin Carroll,et al.  Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) , 2005, The Lancet.

[5]  T. Shibata,et al.  Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Schellens,et al.  Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa). , 2005, The oncologist.

[7]  Huqun,et al.  Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. , 2005, Cancer research.

[8]  Mayumi Ono,et al.  Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenocarcinomas , 2005, Clinical Cancer Research.

[9]  William Pao,et al.  Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Takayuki Kosaka,et al.  Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  F. Hirsch,et al.  Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer , 2005, Current opinion in oncology.

[12]  R. Twombly.  Failing survival advantage in crucial trial, future of Iressa is in jeopardy. , 2005, Journal of the National Cancer Institute.

[13]  S. Toyooka,et al.  The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  György Kéri,et al.  Cellular targets of gefitinib. , 2005, Cancer research.

[15]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[16]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[17]  David Cella,et al.  Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. , 2003, JAMA.

[18]  Masahiro Fukuoka,et al.  Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  G. Verleden,et al.  Prognostic factors in nonsmall cell lung cancer , 2002 .

[20]  M. Brundage,et al.  Prognostic factors in non-small cell lung cancer: a decade of progress. , 2002, Chest.

[21]  徳毛 誠樹.  The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers , 2005 .

[22]  K. Arar,et al.  Real-time genotyping with oligonucleotide probes containing locked nucleic acids. , 2004, Analytical biochemistry.